The scoringsystem usedin chronicphaseThis TKI hasthe mostmetabolicsyndrome60-70% ofpatients withCML presentwith thissymptomNon-pharmacologicaltreatment forCMLI avoid thisdrug classwith bosutinib,nilotinib anddasatinibResponsewhen BCR-ABL1 (IS)is <0.01%TKIs aremajorsubstratesfor this liverenzymeNumber ofblastspresent inacceleratedphaseDrug classthatrevolutionizedCMLtreatmentAfter 3months, I have3% BCR-ABL,I have this TKIresponseThelandmarkfor thefirst TKII want toavoid thisTKI if I donot wantdiarrheaWhen togive H2RAswithdasatinibI have theT315I mutationbut also haveelevated lipasePatients havepresence of thisBCR-ABLproteinindicative ofCML Moderateto highemetogenicrisk TKIsTherecommendedcriteria usedfor acceleratedphaseTreatmentfor blastphaseCMLThe numberof distinctclinicalphases inCMLI failed 3lines of TKIs,I can try thisagent nextThe current5-yearoverallsurvival rateof CMLPercentageof blastspresent inthe blastphaseTranslocationbetweenthese twochromosomesoccur in CMLToo many ofthese bloodcells areabnormal inCMLThe scoringsystem usedin chronicphaseThis TKI hasthe mostmetabolicsyndrome60-70% ofpatients withCML presentwith thissymptomNon-pharmacologicaltreatment forCMLI avoid thisdrug classwith bosutinib,nilotinib anddasatinibResponsewhen BCR-ABL1 (IS)is <0.01%TKIs aremajorsubstratesfor this liverenzymeNumber ofblastspresent inacceleratedphaseDrug classthatrevolutionizedCMLtreatmentAfter 3months, I have3% BCR-ABL,I have this TKIresponseThelandmarkfor thefirst TKII want toavoid thisTKI if I donot wantdiarrheaWhen togive H2RAswithdasatinibI have theT315I mutationbut also haveelevated lipasePatients havepresence of thisBCR-ABLproteinindicative ofCML Moderateto highemetogenicrisk TKIsTherecommendedcriteria usedfor acceleratedphaseTreatmentfor blastphaseCMLThe numberof distinctclinicalphases inCMLI failed 3lines of TKIs,I can try thisagent nextThe current5-yearoverallsurvival rateof CMLPercentageof blastspresent inthe blastphaseTranslocationbetweenthese twochromosomesoccur in CMLToo many ofthese bloodcells areabnormal inCML

Chronic Myeloid Leukemia BINGO - Call List

(Print) Use this randomly generated list as your call list when playing the game. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
B
2
O
3
G
4
O
5
I
6
B
7
I
8
O
9
N
10
I
11
G
12
B
13
G
14
N
15
B
16
G
17
N
18
I
19
O
20
O
21
I
22
B
23
G
24
N
  1. B-The scoring system used in chronic phase
  2. O-This TKI has the most metabolic syndrome
  3. G-60-70% of patients with CML present with this symptom
  4. O-Non-pharmacological treatment for CML
  5. I-I avoid this drug class with bosutinib, nilotinib and dasatinib
  6. B-Response when BCR-ABL1 (IS) is <0.01%
  7. I-TKIs are major substrates for this liver enzyme
  8. O-Number of blasts present in accelerated phase
  9. N-Drug class that revolutionized CML treatment
  10. I-After 3 months, I have 3% BCR-ABL, I have this TKI response
  11. G-The landmark for the first TKI
  12. B-I want to avoid this TKI if I do not want diarrhea
  13. G-When to give H2RAs with dasatinib
  14. N-I have the T315I mutation but also have elevated lipase
  15. B-Patients have presence of this BCR-ABL protein indicative of CML
  16. G-Moderate to high emetogenic risk TKIs
  17. N-The recommended criteria used for accelerated phase
  18. I-Treatment for blast phase CML
  19. O-The number of distinct clinical phases in CML
  20. O-I failed 3 lines of TKIs, I can try this agent next
  21. I-The current 5-year overall survival rate of CML
  22. B-Percentage of blasts present in the blast phase
  23. G-Translocation between these two chromosomes occur in CML
  24. N-Too many of these blood cells are abnormal in CML